The Singapore Dengue Consortium was first established in 2003 and consists of six healthcare and research companies who have joined forces to study mosquito-borne diseases. These are the Environmental Health Institute of Singapore, the Genome Institute of Singapore, SingHealth Group, National Healthcare Group, the Novartis Institute for Tropical Diseases and Temasek Life Sciences Laboratory. Membership of the consortium was expanded to eleven healthcare and research companies on June 21, 2007.
 

The intention of the consortium is to explore ways to better understand and manage dengue infection and ultimately minimize the incidence of dengue in Singapore. Consortium members will be able to leverage on each other's strengths and capabilities in terms of clinical management, laboratory diagnosis and viral research in order to accelerate the diagnosis of dengue, determine the serotype of dengue as well as its full genome sequence, and understand what role the genes of dengue virus play in causing the different types of dengue diseases with different severity.